Skip to main content
SpringerLink
Log in

Preclinical safety testing of species-specific proteins produced with recombinant DNA-technqiues

An attempt to transfer current experience into future testing strategies

  • Review
  • Published:
Archives of Toxicology Aims and scope Submit manuscript

Summary

Preclinical toxicity studies in animals with species-specific recombinant DNA products have now been performed for several years. An interim statement on the significance of these animal tests and their ability to predict adverse effects in humans therefore appears indicated, with the aim of deducing future testing strategies. The experience accumulated so far shows that the animal models have failed to predict adverse effects subsequently observed in man. Immunogenicity of these proteins further restricted the usefulness of standard toxicity tests. There is also increasing evidence that animal tests on the toxic potential of impurities contained in the products are markedly inferior in sensitivity to analytical and quality control methods.

Thus, modified testing programs are proposed to demonstrate safety rather than target organ toxicity using rodents and small non-rodent species and restricted dosing; furthermore the study duration should be limited by the detection of immunogenic responses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Ames BN (1975) Identifying environmental chemicals causing mutations and cancer. Science 204: 587–593

    Google Scholar 

  • Bindon C, Czerniecki M, Ruell P, Edwards A, McCarthy WH, Harris R, Hersey P (1983) Clearance rates and systemic effects of intravenously administered interleukin-2 (IL-2) containing preparations in human subjects. Br J Cancer 47: 123–133

    Google Scholar 

  • Beck F (1976) Comparative placental morphology and function. Environ Health Perspect 18: 5–12

    Google Scholar 

  • Bongiovanni AM, Digeorge AM, Grumbach MM (1959) Masculinization of the female infant associated with estrogen therapy alone during gestation. J Clin Endocrinol Metab 19: 1004–1010

    Google Scholar 

  • Brent RL (1965) Effects of proteins, antibodies, and autoimmune phenomena upon conception and embryogenesis. In: Wilson JG, Warkany J (eds): Teratology principles and techniques. The University of Chicago Press, Chicago and London, pp 219–233

    Google Scholar 

  • Brent RL, Jensen M (1978) Immunological aspects of development. In: Wilson JG, Fraser FC (eds): Handbook of teratology; Vol. 4, Plenum Press, New York and London, pp 339–396

    Google Scholar 

  • Brown GC (1966) Recent advances in the viral ethiology of cogenital anomalies. In: Wollam DHM (ed): Advances in teratology; vol. 1, Logos Press, Dublin, pp 55–80

    Google Scholar 

  • Bruni G, Rossi GL, Celasco G, Falconi G (1975) Effect of estriol and quinestradiol administered to the pregnant rat on sexual differentiation of the fetus. Ann Obstet Gynecol Med Perinat 96: 83–90

    Google Scholar 

  • Cooper JE (1985) Ethics and laboratory animals. Vet Rec 116: 594–595

    Google Scholar 

  • Deighton GH (1983) Document 28482, Public Health Service, Department of Health and Human Services, Freedom of Information. Staff. May 14

  • Dziewanowska ZE, Bernhardt LL, Fein S (1984) Human clinical trials of bacteria-derived human alpha interferon. In: Bollon AP(ed): Recombinant DNA products: insulin, interferon and growth hormone. CRC Press Inc., Boca Raton, Florida, pp 115–128

    Google Scholar 

  • Edwards MJ (1974) The effect of hyperthermia on pregnancy and prenatal development. In: Woollam DHM, Morriss GM (eds): Experimental embryology and teratology; Vol. 1, Elek Science, London pp 90–133

    Google Scholar 

  • Falchetti R, Silvestri S, Battaglia A, Caprino L (1983) Toxicological evaluation of immunomodulating drugs. In: Zbinden G, Cohadon F, Detaille JY, Mazue (eds): Current problems in drug toxicology. Libbey Eurotext, Paris and London, pp 248–263

    Google Scholar 

  • Feldberg W, Scott GM (1984) Interferon fever in cats. J Physiol (London) 355, 28 P

    Google Scholar 

  • Finter NB, Woodrooffe J, Priestman TJ (1982) Monkeys are insensitive to pyrogenic effects of human alpha-interferons. Nature (London) 298: 301

    Google Scholar 

  • Garner RC (1980) Carcinogenesis by fungal products. Br Med Bull 36: 47–52

    Google Scholar 

  • Greene RR, Burrill MW, Ivy AC (1940) Experimental intersexuality. The effect of oestrogens on the antenatal sexual development of the rat. Am J Anat 67: 305–345

    Google Scholar 

  • Gregg NM (1941) Congenital cataract following German measles in mother. Trans Ophthal Soc Aust 3: 35–46

    Google Scholar 

  • Gresser I, Morel-Maroger L, Chatelet F, Maury C, Tovey M, Banda M, Buywid J, Delauche M (1979) Delay in growth and the development of nephritis in rats treated with interferon preparations in the neonatal period. Am J Pathol 95: 329–346

    Google Scholar 

  • Gresser I, Aguet M, Morel-Maroger L, Woodrow D, Puvion-Dutilleul F, Guillon J, Maury C (1981) Electrophoretically pure mouse interferon inhibits growth, induces liver and kidney lesions and kills suckling mice. Am J Pathol 102: 396–402

    Google Scholar 

  • Hertz F, Deghenghi R (1985) Effect of rat and human beta-interferons on hyperacute experimental allergic encephalomylitis in rats. Agents Actions 16: 397–403

    Google Scholar 

  • Honisberger L, Fielding JW, Priestman TJ (1983) Neurological effects of recombinant human interferon. Br Med J 286: 719

    Google Scholar 

  • Jacobs AD, Naiem F, Champlin RE, Golde DW (1985) Toxicity and bone marrow response of patients with hairy cell leukemia treated with biosynthetic (recombinant) alpha-2-interferon. Blut 50: 33–34

    Google Scholar 

  • Kataoka I, Sakurai Y (1980) Interferon, preclinical basis for clinical trials with fibroblast interferon in Japan. Cancer Treatment Rev 7: 253–256

    Google Scholar 

  • Kern P, Toy J, Dietrich M (1985) Preliminary clinical observations with recombinant interleukin-2 in patients with AIDS or LAS, Blut 50: 1–6

    Google Scholar 

  • Kurent JE, Sever JL (1977) Infectious diseases. In: Wilson JG, Fraser FC (eds): Handbook of teratology; vol. 1, Plenum Press, New York and London, pp 225–259

    Google Scholar 

  • Lloyd JB, Williams KE, Beck F (1974) Placental function, a target for teratogens. Biochem Soc Trans 2: 702–703

    Google Scholar 

  • Luster MI, Dean JH, Moore JA (1982) Evaluation of immune functions in toxicology. In: Hayes AW (ed) Principles and methods of toxicology; Raven Press, New York, pp 561–586

    Google Scholar 

  • McCann J, Choi E, Yamasaki E, Ames BN (1975) Detection of carcinogens as mutagens in the Salmonella/microsome test: Assay of 300 chemicals. Proc Natl Acad Sci 72: 5135–5139

    Google Scholar 

  • Mier JW, Souza LM, Allegretta M, Boone T, Bernheim HA, Dinarello CA (1985) Dissimilarities between purified human interleukin-2 in the induction of fever, brain prostaglandin, and acute phase protein synthesis. J Biol Response Modif 4: 35–45

    Google Scholar 

  • Mongensen KE, Pyhaelae L, Cantell K (1975) Raising antibodies to human leukocyte interferon. Acta Pathol Microbiol Scand, Sec. B, 83: 443–450

    Google Scholar 

  • Obert H-J (1983) Interferon: Französische Studien abgebrochen. Muench Med Wschr 125: 13

    Google Scholar 

  • Omata M, Imazeki F, Yokosuda O, Ito Y, Uchiumi K, Mori J (1985) Recombinant leukocyte A interferon treatment in patients with chronic hepatitis B virus infection: pharmacokinetics, tolerance, and biologic effects. Gastroenterology 88: 870–880

    Google Scholar 

  • Ornoy A, Altshuler G (1975) Placental mediated endotoxin rat embryopathy. Anat Rec 181: 441

    Google Scholar 

  • Otto U, Huland H, Zschaber R (1985) Recombinant interferon gamma: first results of clinical phase II study in patients with metastatic renal cell carcinoma and experimental studies of human renal cell carcinoma transplanted into nude mice. J Urol 133: 155A

  • Peters PWJ, Garbis-Berkvens JM (1985) Development of the maternal-embryonic/fetal exchange: Morphology and function. International Symposium-Workshop: Pharmacokinetics in Teratogenesis. Berlin-West, 13–15 September (in press)

  • Petricciani JC (1983) An overview of safety and regulatory aspects on the new biotechnology. Regul Toxicol Pharmacol 3: 428–433

    Google Scholar 

  • Pyhaelae L, Rimaila-Paernaenen E, Kekomaeki R, Kostiainen E, Cantell K (1978) Toxicity studies with human leukocyte interferon in newborn rabbits. Acta Pathol Microbiol Scand, Sect. C, 86: 45–51

    Google Scholar 

  • Redmond GP (1979) Effects of drugs on intrauterine growth. Clin Perinatol 6: 5–19

    Google Scholar 

  • Renoux G (1983) Les exigences de l'evaluation immunopharmacologique d'un medicament. In: Zbinden G, Cohadon F, Detaille JY, Mazue G (eds): Current problems in toxicology. Libbey Eurotext, Paris and London, pp 310–314

    Google Scholar 

  • Rohatiner AZS, Prior PF, Burton AC, Smith AT, Balkwill FR, Lister TA (1983) Central nervous system toxicity of interferon. Br J Cancer 47: 419–422

    Google Scholar 

  • Roney CS, Rossi CR, Smith PC, Lauermann LC, Spano JS, Hanrahan LA, Williams JC (1985) Effect of human leukocyte A interferon on prevention of infectious bovine rhinotracheitis virus infection in cattle. Am J Vet Res 46: 1251–1255

    Google Scholar 

  • Ronneberger H, Hilfenhaus J (1983) Toxicity studies with human fibroblast interferon. Arch Toxicol Suppl 6: 391–394

    Google Scholar 

  • Schellekens H, v. d. Meide PH (1983) Animal studies with interferon. In: de Mayer E, Schellekens H (eds): The biology of the interferon system. Elsevier Scientific Publishers; Amsterdam, New York, Oxford, pp 409–418

    Google Scholar 

  • Schellekens H, de Reus A, Bolhuis R, Fountonlakis M, Schein C, Escodi J, Nagata S, Weissmann C (1981a) Comparative antiviral efficiency of leukocyte and bacterially produced human alpha-interferon in rhesus monkeys. Nature (London) 292: 775–776

    Google Scholar 

  • Schellekens H, Stitz LW, de Reus A, Weimar W, Cantell K (1981b) Antiviral activity of human leukocyte interferon in rhesus monkeys and marmosets. Antiviral Res 1: 281–285

    Google Scholar 

  • Schellekens H, van Erd PMCA, de Reus A, Weck PK, Stebbing N (1982) Antiviral and side effects of interferons produced by recombinant DNA techniques as tested in rhesus monkeys. Antiviral Res 2: 313–318

    Google Scholar 

  • Schellekens H, de Reus A, v. d. Meide PH (1984) The chimpanzee as a model to test the side effects of human interferons. J Med Primatol 13: 235–245

    Google Scholar 

  • Scott GM, Secher DS, Flowers D, Bate J, Cantell K, Tyrrell DAJ (1981) Toxicity of interferon. Br Med J 282: 1345–1348

    Google Scholar 

  • Scott GM, Wallace J, Tyrrell DAJ, Cantell K, Secher DS, Stewart WE (1982) Interim report on studies on “toxic” effects of human leukocyte-derived interferon-alpha (HuIFN-a). J Interferon Res 2: 127–130

    Google Scholar 

  • Sechser T, Raskova H, Jiricka E (1974) Contribution of toxins to embryotoxicity. Proc Eur Soc Stud Drug Toxic 16: 169–173

    Google Scholar 

  • Sherwin SA, Knost JA, Fein S, Abrams PG, Foon KA, Ochs JJ, Schoenberger C, Maluish AE, Oldham RK (1982) A multiple dose phase I trial of recombinant leukocyte A interferon in cancer patients. JAMA 248: 2461–2466

    Google Scholar 

  • Shoham J (1985) Specific safety problems of inappropriate immune responses to immunostimulating agents. TIPS, April 1985: 178–182

  • Sriskandau K, Toe DEH, Pettingale KW (1985) Nephrotic syndrome during treatment with interferon. Br Med J 290: 1590–1591

    Google Scholar 

  • Stebbing N, Weck PK (1984) Preclinical assessment of biological properties of recombinant DNA derived human interferons. In: Bollon AP (ed): Recombinant DNA products: insulin, interferon and growth hormone. CRC Press Inc., Boca Raton, Florida, pp 75–114

    Google Scholar 

  • Stebbing N, Weck PK, Fenno JT, Estell DA, Rinderknecht E (1983) Antiviral effects of bacteria derived human leukocyte interferons against encephalomyocarditis virus infection of squirrel monkeys. Arch Virol 76: 365–372

    Google Scholar 

  • Trocheris I (1982) Interferon in France: Trial condemned. Nature 300: 677

    Google Scholar 

  • Trown PW, Wills RJ, Kamm JJ (1985) Review of the preclinical development of Roferon-A. Symposium on developments in the treatment of malignant and viral disorders with recombinant interferon. Osaka, Japan, June 22

  • Trown PW, Wills RJ, Kamm JJ (1986) The preclinical development of Roferon-A. Cancer 57: 1648–1656

    Google Scholar 

  • Wade N (1978) New vaccine may bring man and chimpanzee into tragic conflict. Science 200: 1027–1030

    Google Scholar 

  • Wagstaff J, Chadwick G, Howell A, Thatcher N, Scarffe JH, Crowther D (1984) A phase I toxicity study of human rDNA interferon in patients with solid tumours. Cancer Chemother Pharmacol 13: 100–105

    Google Scholar 

  • Warshauer DM (1985) Primacy among the primates: killing chimpanzees to help humans. JAMA 254: 356

    Google Scholar 

  • Wild D, Gocke E, Harnasch D, Kaiser G, King M-T (1985) Differential mutagenic activity of IQ (2-amino-3-methylimidazo-[4,5-f]quinoline) in Salmonella typhimurium strains in vitro and in vivo, in Drosophila, and in mice. Mutat Res 156: 93–102

    Google Scholar 

  • Weissmann C, Schellekens H (1982) Reply to Finter et al. Nature (London) 298: 301

    Google Scholar 

  • Weimar W, Stitz LW, Billiau A, Cantell K, Schellekens H (1980) Prevention of vaccinia lesions in rhesus monkeys by human leukocyte and fibroblast interferon. J Gen Virol 48: 25–30

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Biological Pharmaceutical Research Department, F. Hoffmann-La Roche & Co. Ltd., CH-4002, Basle, Switzerland

    Kampe Teelmann

  2. Department of Experimental Pathology, Dr. Karl Thomae GmbH, D-7950, Biberach, Federal Republic of Germany

    Christoph Hohbach & Horst Lehmann

Authors
  1. Kampe Teelmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christoph Hohbach
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Horst Lehmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

The International Working group

Additional information

Working Group Participants: K. Hoffmann, G. Schlueter, H. D. Schlumberger, E.-A. Loebbecke, Bayer AG; H. Ronneberger, Behringwerke AG; H. Stoetzer, Boehringer Ingelheim KG; R. Ziel, P. Graepel, Ciba-Geigy AG; H. H. Donaubauer, D. Mayer, Hoechst AG; K. Teelmann, E. Theiss, F. Hoffmann-La Roche & Co AG; R. Omilian-Rosso, B. Ryffel, Sandoz AG; Ch. Hohbach, H. Lehmann, M. Baumeister, L. Luetzen, Thomae GmbH

Rights and permissions

Reprints and permissions

About this article

Cite this article

Teelmann, K., Hohbach, C., Lehmann, H. et al. Preclinical safety testing of species-specific proteins produced with recombinant DNA-technqiues. Arch Toxicol 59, 195–200 (1986). https://doi.org/10.1007/BF00290537

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00290537

Key words

Search

Navigation